Elastofibroma: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 21: Line 21:
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
==Causes==
==Causes==
* [Disease name] may be caused by either [cause1], [cause2], or [cause3].
* Elastofibroma may be caused by either trauma, genetic mutation, or systemic enzyme defects.
* [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
 
* There are no established causes for [disease name].
==Differentiating [disease name] from other Diseases==
==Differentiating [disease name] from other Diseases==
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

Revision as of 20:00, 11 April 2016

WikiDoc Resources for Elastofibroma

Articles

Most recent articles on Elastofibroma

Most cited articles on Elastofibroma

Review articles on Elastofibroma

Articles on Elastofibroma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Elastofibroma

Images of Elastofibroma

Photos of Elastofibroma

Podcasts & MP3s on Elastofibroma

Videos on Elastofibroma

Evidence Based Medicine

Cochrane Collaboration on Elastofibroma

Bandolier on Elastofibroma

TRIP on Elastofibroma

Clinical Trials

Ongoing Trials on Elastofibroma at Clinical Trials.gov

Trial results on Elastofibroma

Clinical Trials on Elastofibroma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Elastofibroma

NICE Guidance on Elastofibroma

NHS PRODIGY Guidance

FDA on Elastofibroma

CDC on Elastofibroma

Books

Books on Elastofibroma

News

Elastofibroma in the news

Be alerted to news on Elastofibroma

News trends on Elastofibroma

Commentary

Blogs on Elastofibroma

Definitions

Definitions of Elastofibroma

Patient Resources / Community

Patient resources on Elastofibroma

Discussion groups on Elastofibroma

Patient Handouts on Elastofibroma

Directions to Hospitals Treating Elastofibroma

Risk calculators and risk factors for Elastofibroma

Healthcare Provider Resources

Symptoms of Elastofibroma

Causes & Risk Factors for Elastofibroma

Diagnostic studies for Elastofibroma

Treatment of Elastofibroma

Continuing Medical Education (CME)

CME Programs on Elastofibroma

International

Elastofibroma en Espanol

Elastofibroma en Francais

Business

Elastofibroma in the Marketplace

Patents on Elastofibroma

Experimental / Informatics

List of terms related to Elastofibroma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Overview

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • Elastofibroma, also called elastofibroma dorsi, is an ill-defined fibroelastic tumor-like condition made up of enlarged and irregular elastic fibers. [1] [2]
  • The genetic mutation in has been associated alterations of short arm of chromosome 1 with the development of elastofibroma.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

  • Elastofibroma may be caused by either trauma, genetic mutation, or systemic enzyme defects.

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly

patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than

[gender 2].

  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followedup every [duration]. Followup testing includes [test 1], [test 2], and [test 3].

References

  1. Chandrasekar, C. R.; Grimer, R. J.; Carter, S. R.; Tillman, R. M.; Abudu, A.; Davies, A. M.; Sumathi, V. P. (2008). "Elastofibroma Dorsi: An Uncommon Benign Pseudotumour". Sarcoma. 2008: 1. doi:10.1155/2008/756565. PMC 2276598. PMID 18382611.
  2. Briccoli, A.; Casadei, R.; Di Renzo, M.; Favale, L.; Bacchini, P.; Bertoni, F. (2000). "Elastofibroma dorsi". Surgery today. 30 (2): 147–152. doi:10.1007/pl00010063. PMID 10664338.